Not all imatinib resistance in CML are BCR-ABL kinase domain mutations

@article{Wei2006NotAI,
  title={Not all imatinib resistance in CML are BCR-ABL kinase domain mutations},
  author={Yuan Wei and Mats Hardling and Bob Olsson and Rahil Hezaveh and Anne Ricksten and Dick Stockelberg and Hans Wadenvik},
  journal={Annals of Hematology},
  year={2006},
  volume={85},
  pages={841-847}
}
Point mutations within the ABL kinase domain of the BCR-ABL gene are associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML). To obtain more information about the association between BCR-ABL mutations and type of imatinib resistance, we studied 30 early chronic phase (CP) CML patients, commencing imatinib therapy, using a conventional sequencing technique. Seven patients treated in late CP and three patients treated in the accelerated phase were included for… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

  • JS Khorashad, AnandM, +8 authors J Kaeda
  • Leukemia
  • 2006
1 Excerpt